Detection of Clinical Mesenchymal Cancer Cells from Bladder Wash Urine for Real-Time Detection and Prognosis

Khoo, Bee Luan; Bouquerel, Charlotte; Durai, Pradeep; Anil, Sarannya; Goh, Benjamin; Wu, Bingcheng; Raman, Lata; Mahendran, Ratha; Thamboo, Thomas Paulraj; Chiong, Edmund; Lim, Chwee Teck

doi:10.3390/cancers11091274

Cited by 18 publications

(14 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the EMT process, the invasion and metastasis rate of tumors increases, and the resistance of chemotherapy drugs is improved (15)(16)(17). There are phenotype and morphological changes of cancer cells formed by EMT in circulating tumor cells of HCC (18,19).…”

Section: Introductionmentioning

confidence: 99%

Association of Preoperative NANOG-Positive Circulating Tumor Cell Levels With Recurrence of Hepatocellular Carcinoma

Yuan

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundCancer stem cells (CSCs) and Circulating tumor cells (CTCs) have been proposed as fundamental causes for the recurrence of hepatocellular carcinoma (HCC). CTCs isolated from patients with HCC illustrate a unique Nanog expression profile analysis. The aim of this study was to enhance the prediction of recurrence and prognosis of the CTC phenotype in patients with HCC by combining Nanog expression into a combined forecasting model.Subjects, Materials, and MethodsWe collected 320 blood samples from 160 patients with HCC cancer before surgery and used CanPatrol™ CTC enrichment technology and in situ hybridization (ISH) to enrich and detect CTCs and CSCs. Nanog expression in all CTCs was also determined. In addition, RT-PCR and immunohistochemistry were used to study the expression of Nanog, E-Cadherin, and N-Cadherin in liver cancer tissues and to conduct clinical correlation studies.ResultsThe numbers of EpCAM mRNA+ CTCs and Nanog mRNA+ CTCs were strongly correlated with postoperative HCC recurrence (CTC number (P = 0.03), the total number of mixed CTCS (P = 0.02), and Nanog> 6.7 (P = 0.001), with Nanog > 6.7 (P = 0.0003, HR = 2.33) being the most crucial marker. There are significant differences in the expression of Nanog on different types of CTC: most Epithelial CTCs do not express Nanog, while most of Mixed CTC and Mesenchymal CTC express Nanog, and their positive rates are 38.7%, 66.7%, and 88.7%, respectively, (P=0.0001). Moreover, both CTC (≤/> 13.3) and Nanog (≤/>6.7) expression were significantly correlated with BCLC stage, vascular invasion, tumor size, and Hbv-DNA (all P < 0.05). In the young group and the old group, patients with higher Nanog expression had a higher recurrence rate. (P < 0.001).ConclusionsThe number of Nanog-positive cells showed positive correlation with the poor prognosis of HCC patients. The detection and analysis of CTC markers (EpCAM and CK8, 18, CD45 Vimentin,Twist and 19) and CSCs markers (NANOG) are of great value in the evaluation of tumor progression.

show abstract

Section: Introductionmentioning

confidence: 99%

Association of Preoperative NANOG-Positive Circulating Tumor Cell Levels With Recurrence of Hepatocellular Carcinoma

Yuan

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Recent studies have employed inertial microfluidics to specifically separate EBCCs from bladder wash urine 115 . Such techniques were previously optimized for the detection of circulating tumor cells (CTCs) from blood-based liquid biopsy 116 .…”

Section: Upcoming Technological Advancements To Facilitate Biomarker mentioning

confidence: 99%

Urine biopsy technologies: Cancer and beyond

Chen¹,

Liao²,

Li³

et al. 2020

Theranostics

Self Cite

View full text Add to dashboard Cite

Since the discovery of circulating tumor cells in 1869, technological advances in the study of biomarkers from liquid biopsy have made it possible to diagnose disease in a less invasive way. Although blood-based liquid biopsy has been used extensively for the detection of solid tumors and immune diseases, the potential of urine-based liquid biopsy has not been fully explored. Advancements in technologies for the harvesting and analysis of biomarkers are providing new opportunities for the characterization of other disease types. Liquid biopsy markers such as exfoliated bladder cancer cells, cell-free DNA (cfDNA), and exosomes have the potential to change the nature of disease management and care, as they allow a cost-effective and convenient mode of patient monitoring throughout treatment. In this review, we addressed the advancement of research in the field of disease detection for the key liquid biopsy markers such as cancer cells, cfDNA, and exosomes, with an emphasis on urine-based liquid biopsy. First, we highlighted key technologies that were widely available and used extensively for clinical urine sample analysis. Next, we presented recent technological developments in cell and genetic research, with implications for the detection of other types of diseases, besides cancer. We then concluded with some discussions on these areas, emphasizing the role of microfluidics and artificial intelligence in advancing point-of-care applications. We believe that the benefits of urine biopsy provide diagnostic development potential, which will pave opportunities for new ways to guide treatment selections and facilitate precision disease therapies.

show abstract

“…Recent advances in detection and sequencing technology have contributed to clinical determination of genomic heterogeneity in subpopulations of BC patients. For example, the detection of invasive mesenchymal exudative bladder cancer cells (EBCCs) from urine using a microfluidic enrichment device has a high sensitivity (93.3%), therefore, the enumeration and cytological analysis of EBCCs may serve as a complementary tool for clinical real‐time detection [113]. In nasopharyngeal cancer, a label‐free and modification‐free nanotechnology based on surface‐enhanced Raman spectroscopy was employed for cfDNA analysis with an ideal diagnostic sensitivity of 83.3% and specificity of 82.5% [114].…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Tumor heterogeneity and the potential role of liquid biopsy in bladder cancer

Huang

2020

Cancer Communications

View full text Add to dashboard Cite

Bladder cancer (BC) is a heterogeneous disease that characterized by genomic instability and a high mutation rate. Heterogeneity in tumor may partially explain the diversity of responses to targeted therapies and the various clinical outcomes. A combination of cytology and cystoscopy is the standard methodology for BC diagnosis, prognosis, and disease surveillance. However, genomics analyses of single tumor-biopsy specimens may underestimate the mutational burden of heterogeneous tumors. Liquid biopsy, as a promising technology, enables analysis of tumor components in the bodily fluids, such as blood and urine, at multiple time points and provides a minimally invasive approach that can track the evolutionary dynamics and monitor tumor heterogeneity. In this review, we describe the multiple faces of BC heterogeneity at the genomic and transcriptional levels and how they affect clinical care and outcomes. We also summarize the outcomes of liquid biopsy in BC, which plays a potential role in revealing tumor heterogeneity. Finally, we discuss the challenges that must be addressed before liquid biopsy can be widely used in clinical treatment.

show abstract

Detection of Clinical Mesenchymal Cancer Cells from Bladder Wash Urine for Real-Time Detection and Prognosis

Cited by 18 publications

References 50 publications

Association of Preoperative NANOG-Positive Circulating Tumor Cell Levels With Recurrence of Hepatocellular Carcinoma

Association of Preoperative NANOG-Positive Circulating Tumor Cell Levels With Recurrence of Hepatocellular Carcinoma

Urine biopsy technologies: Cancer and beyond

Tumor heterogeneity and the potential role of liquid biopsy in bladder cancer

Contact Info

Product

Resources

About